Crescent Biopharma (CBIO) Receivables - Other (2013 - 2025)
Crescent Biopharma (CBIO) reported Receivables - Other of $78762.0 for Q1 2025, down 28.36% year-over-year from $109946.0 in Q1 2024, and down 42.33% quarter-over-quarter from $136580.0 in Q4 2024.
Crescent Biopharma (CBIO) Receivables - Other (2013 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has 13 years of Receivables - Other data on file, last reported at $78762.0 in Q1 2025.
- Receivables - Other for Q1 2025 came in at $78762.0, down 28.36% year-over-year; the trailing twelve-month figure through Mar 2025 was $78762.0 (down 28.36% YoY), and the FY2024 annual result was $136580.0, down 22.32% from the prior year.
- Receivables - Other retreated to $78762.0 in Q1 2025 per CBIO's latest filing, from $136580.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $444568.0 in Q1 2021 and troughed at $1347.0 in Q4 2021.
- A 5-year average of $122088.6 and a median of $109946.0 in 2024 frame the typical range for Receivables - Other.
- On a YoY basis, Receivables - Other climbed as much as 10591.61% in 2022 and fell as far as 98.93% in 2022.
- A 5-year view of Receivables - Other shows it stood at $1347.0 in 2021, then jumped by 10591.61% to $144016.0 in 2022, then advanced by 22.08% to $175820.0 in 2023, then declined by 22.32% to $136580.0 in 2024, then slumped by 42.33% to $78762.0 in 2025.
- Business Quant data shows CBIO's Receivables - Other at $78762.0 in Q1 2025, $136580.0 in Q4 2024, and $50255.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 78,762.00 |
| Mar 31, 2025 | 78,762.00 |
| Dec 31, 2024 | 136,580.00 |
| Dec 31, 2024 | 136,580.00 |
| Sep 30, 2024 | 50,255.00 |
| Sep 30, 2024 | 50,255.00 |
| Jun 30, 2024 | 76,710.00 |
| Jun 30, 2024 | 76,710.00 |
| Mar 31, 2024 | 109,946.00 |
| Mar 31, 2024 | 109,946.00 |
| Dec 31, 2023 | 175,820.00 |
| Dec 31, 2023 | 175,820.00 |
| Sep 30, 2023 | 188,949.00 |
| Sep 30, 2023 | 188,949.00 |
| Jun 30, 2023 | 215,368.00 |
| Jun 30, 2023 | 215,368.00 |
| Mar 31, 2023 | 234,114.00 |
| Mar 31, 2023 | 234,114.00 |
| Dec 31, 2022 | 144,016.00 |
| Dec 31, 2022 | 144,016.00 |